PMID- 19897395
OWN - NLM
STAT- MEDLINE
DCOM- 20100222
LR  - 20171116
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 35
IP  - 6
DP  - 2009 Dec
TI  - Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes.
PG  - 484-9
LID - 10.1016/j.diabet.2009.06.003 [doi]
AB  - BACKGROUND: Erectile dysfunction (ED) is a frequent comorbidity in patients with 
      type 2 diabetes mellitus (T2DM), and is now increasingly considered a surrogate 
      marker of endothelial dysfunction as well as a sentinel predictor of new-onset 
      macroangiopathic events. Less attention, however, has been directed at the 
      potential association of ED and microangiopathy in hyperglycaemic states. 
      METHODS: We analyzed 221 consecutive male T2DM outpatients in whom ED was 
      assessed by the International Index of Erectile Function (IIEF-5) questionnaire. 
      ED(+) patients (IIEF-5 1-20; n=83) were compared with an age-matched ED(-) cohort 
      (IIEF-5 21-25; n=51), with similar diabetes duration, in terms of cardiovascular 
      (CV) risk factors, micro-/macroangiopathy and the United Kingdom Prospective 
      Diabetes Study (UKPDS) risk score. RESULTS: Mean age and diabetes duration were 
      58 and 10 years, respectively. IIEF-5 score (1 S.D) was 23 (1) in ED(-) vs 11 (6) 
      in ED(+). Anamnestic impotence and erectogenic drug use were reported by 52% and 
      36%, respectively, of ED(+) vs 12% and 8%, respectively, of ED(-) (P<0.0002 and 
      P<0.0001, respectively). The metabolic syndrome prevalence (88% vs 64%; P=0.002) 
      and central adiposity markers (waist, waist/height and visceral fat) were all 
      significantly higher in ED(+). HbA(1c) was similar in both groups: 7.5% (1.3%), 
      and there were also no significant differences in smoking, blood pressure, HOMA 
      insulin sensitivity, cholesterol and glomerular filtration rate. However, 
      prevalences of retinopathy, polyneuropathy and elevated albuminuria, and the 
      composite endpoint of peripheral artery disease, transient ischaemic attacks 
      and/or stroke, were markedly increased in ED(+) (all P<0.05). No differences were 
      observed in coronary artery disease prevalence or in the UKPDS 10-year CV risk 
      between the two ED groups. CONCLUSION: IIEF-5-defined ED in men with T2DM is 
      associated with a marked increase in the metabolic syndrome, central adiposity 
      and microangiopathy. These data suggest that diagnosing ED in T2DM warrants 
      detailed screening and monitoring for microangiopathy in target organs.
FAU - Hermans, Michel P
AU  - Hermans MP
AD  - Endocrinology & Nutrition, Cliniques universitaires St-Luc, DIAB 54.74 Tour 
      Claude Bernard +1, Bruxelles, Belgium. michel.hermans@diab.ucl.ac.be
FAU - Ahn, Sylvie A
AU  - Ahn SA
FAU - Rousseau, Michel F
AU  - Rousseau MF
LA  - eng
PT  - Journal Article
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cardiovascular Diseases/etiology/physiopathology
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/complications/*physiopathology
MH  - Diabetic Angiopathies/complications/*physiopathology
MH  - Humans
MH  - Impotence, Vasculogenic/*etiology/physiopathology
MH  - Longitudinal Studies
MH  - Male
MH  - Metabolic Syndrome/complications/physiopathology
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - United Kingdom
EDAT- 2009/11/10 06:00
MHDA- 2010/02/23 06:00
CRDT- 2009/11/10 06:00
PHST- 2009/01/23 00:00 [received]
PHST- 2009/05/28 00:00 [revised]
PHST- 2009/06/03 00:00 [accepted]
PHST- 2009/11/10 06:00 [entrez]
PHST- 2009/11/10 06:00 [pubmed]
PHST- 2010/02/23 06:00 [medline]
AID - S1262-3636(09)00177-3 [pii]
AID - 10.1016/j.diabet.2009.06.003 [doi]
PST - ppublish
SO  - Diabetes Metab. 2009 Dec;35(6):484-9. doi: 10.1016/j.diabet.2009.06.003.